Prati-Donaduzzi produces about 11.5 billion therapeutic doses per year
Prati-Donaduzzi, Brazil's largest producer of generic drugs*, is among the 150 most innovative companies in the country, according to Valor Inovação Brasil Yearbook, the most relevant innovation publication in the national scenario.
The award ceremony of the 5th edition of the Yearbook took place on Tuesday (2), at Espaço Villa Blue Tree, in São Paulo (SP).
Among 210 Brazilian companies surveyed, Prati-Donaduzzi ranked 112th, growing nine positions compared to 2018. In the past, the ranking was 121st. The research evaluated the innovation practices of companies operating in Brazil in different economic activities.
The ranking was based on five pillars of the chain of innovation: intention to innovate, effort to achieve innovation, obtained results, market evaluation and knowledge generation. The aim was to analyze how each of the pillars is built in companies and how this is reflected in the participants' innovation practices.
According to Eder Fernando Maffissoni, Prati-Donaduzzi CEO, participation in the Yearbook is very important, as it highlights the company's efforts in improving its processes, aiming to contribute more and more to the advancement of science and health quality of Brazilian people.
"Being among the most innovative companies in Brazil is a way to prove the quality of Prati-Donaduzzi, a 100% national industry. It confirms that we are a responsible company, always trying to offer the most modern and safest medicines that benefit millions of Brazilians", says the CEO.
In search of innovation and new market opportunities, Prati-Donaduzzi invested to structure a production facility for Active Pharmaceutical Inputs (APIs) in Toledo, Western Paraná. The industry's debut in the APIs market will be with a pioneering product in the world, the synthetic Cannabidiol.
The product's main advantage is its high purity, excluding the presence of tetrahydrocannabidiol (THC), a psychoactive substance that causes chemical dependence. At the same time, the company is in the final clinical trials of Myalo®, a cannabis-based drug - produced from purified plant extract, indicated for the control of refractory epilepsy crises (the most critical grade of the disease is in children). The research is being produced in partnership with Hospital das Clínicas of USP, campus of Ribeirão Preto. The drug will help improve the quality of life of nearly 700,000 people suffering from the disease in the country. It is expected to be available on the market early in 2020.
Thinking of contributing to improve Brazilians´ health, Prati-Donaduzzi plans to launch 175 drug presentations this year, of which 163 are generic drugs. Of this total, 37 have already been launched. Most of the new products will be used to treat areas of the central nervous system, cardiovascular system and metabolic digestive system.
In 2018, the company launched 37 options of treatment to the population, of which 33 are generic drugs. Currently, Prati-Donaduzzi has in its portfolio 290 presentations of generic drugs that represent 96.34% of the company's revenues.
Prati-Donaduzzi, a completely domestic pharmaceutical industry, specialized in the development and production of generic drugs. Based in Toledo, western Paraná, Prati-Donaduzzi produces about 11.5 billion therapeutic doses per year and has more than 4,300 employees. The company has one of the largest portfolios of generic drugs in Brazil and aims to grow its sales and production capacity by 15% in 2019.
*IQVIA MAT MAIO/2019 PMB + NRC Doses Terapêuticas
INFORMATION TO THE PRESS
(11) 2548-0720 / (11) 2894-5607
Rodrigo Freitas / Maira Manesco